 |
|
|
ABOUT THE COMPANY
Our MissionQuotient Diagnostics has innovative technology for measuring indicators used clinically to assess the risk of long-term complications in diabetes. The first assay to be developed is "% A1C", a test well recognised by clinicians as the gold standard of diabetes management. (A1C is one of the fractions of haemoglobin). This measurement provides a picture of the average glucose control by a patient over the preceding 2-3 months. The majority of A1C tests are currently carried out by samples being sent from a clinic, surgery or physician's office to a central laboratory for analysis and a report. This is a laborious, time-consuming and expensive process, which generally requires the patient to pay a second visit to the doctor or clinician to receive the result. There is a fast-growing worldwide demand for a means to conduct the A1C test within the scope of a single clinic visit. Quotient's mission is to bring to world markets a rapid, easy and inexpensive method of conducting A1C testing at the Point of Care, at full standards of laboratory precision and accuracy. "We now regard A1C as the key measurement to indicate the quality of diabetic control. All clinics aspire to get the result during the visit and to advise the patient in the light of this result and no other". Prof. Steven Bloom, leading UK endocrinologist
|
|
